Discounted Cash Flow (DCF) Analysis Unlevered

Unity Biotechnology, Inc. (UBX)

$0.6099

-0.00 (-0.03%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 0.6099 | undervalue

Operating Data

Year
A/P
2017
Actual
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 1.38---------
Revenue (%)
EBITDA -43.35---------
EBITDA (%)
EBIT -44.66---------
EBIT (%)
Depreciation 1.30---------
Depreciation (%)

Balance Sheet Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Total Cash 86.51---------
Total Cash (%)
Account Receivables 1.38---------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable 2.38---------
Accounts Payable (%)
Capital Expenditure -1.69---------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 0.6,099
Beta 0.638
Diluted Shares Outstanding 55.82
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt -0.01%
Risk-Free Rate
Market Risk Premium
Cost of Equity 6.004
Total Debt 51.56
Total Equity 34.04
Total Capital 85.60
Debt Weighting 60.23
Equity Weighting 39.77
Wacc

Build Up Free Cash

Year
A/P
2017
Actual
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 1.38---------
EBITDA -43.35---------
EBIT -44.66---------
Tax Rate 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
EBIAT -44.66---------
Depreciation 1.30---------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure -1.69-1.26-1.59-0.65------
UFCF -45.04---------
WACC
PV UFCF ---------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 2.38
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt 18.65
Equity Value -
Shares Outstanding 55.82
Equity Value Per Share -